Independent Research


 AS SEEN ON:

TooNiceStocks from time to time initiates its own independent research and coverage. When we do, all eyes are featured on the company as our track record is flawless! The record speaks for itself!

TooNiceStocks is extremely selective as our world famous brand and reputation is on the line every time we feature a company. The company will need to go through our stringent requirements in order for us to complete of world famous due diligence and research.  

Please read our independent research reports & articles picked up by various credible news outlets. Make sure you view our original published on our page <click here>:

TooNiceStocks Initiates Coverage on IntelGenx Corporation (OTCBB IGXT) - Troubled Past Potential Bright Future

Monday, April 4th, 2011 - IntelGenx Corporation (OTCBB: IGXT)  

TooNiceStocks very popular Independent Research is being picked up by many news portals:   

Benzinga.com LINK HERE

Buzztracker.com LINK HERE

PRweb.com LINK HERE  


 

TooNiceStocks Initiates Coverage on Genta Incorporated (OTCQB: GNTA) - A Long History for Long Awaited Data due early Q2 of 2011

Tuesday, March 29, 2011 - Genta Incorporated. (OTCQB: GNTA)  

TooNiceStocks very popular Independent Research is being picked up by many news portals:   

Benzinga.com LINK HERE

Buzztracker.com LINK HERE

PRweb.com LINK HERE 


  

TooNiceStocks Initiates Coverage on Neoprobe Corporation (AMEX: NEOP) - Researching the Near Term Catalyst, Fundamentals and Product Pipeline

Tuesday, March 29, 2011 - Neoprobe Corporation (AMEX: NEOP)  

TooNiceStocks very popular Independent Research is being picked up by many news portals:   

DailyFinance.com LINK HERE

Benzinga.com LINK HERE

PRBusinessnews.com LINK HERE

Allvoices.com LINK HERE 


TooNiceStocks Initiates Coverage on CorMedix Inc. (AMEX: CRMD) Near Term Catalyst and Recent Institutional Interest 

Monday, March 28, 2011 - CorMedix Inc. (AMEX: CRMD)  

TooNiceStocks very popular Independent Research is being picked up by many news portals:   

Benzinga.com LINK HERE

Allvoices.com.com LINK HERE

BioPortfolio.com LINK HERE

Proactivenewsroom.com LINK HERE 


     

TooNiceStocks Initiates Coverage on Corcept Therapeutics Inc. (NASDAQ: CORT) Evaluating the Benefits of Corlux 

Tuesday, March 22, 2011 - Concept Therapeutics Inc. (NASDAQ: CORT)  

TooNiceStocks very popular Independent Research is being picked up by many news portals:  

Benzinga.com LINK HERE

BioPortfolio.com LINK HERE 

Allvoices.com LINK HERE 


TooNiceStocks Initiates Coverage on Adeona Pharmaceuticals, Inc. Near Term Catalyst Brewing and Long Term Possibilities

Monday, March 18, 2011 - Adeona Pharmaceuticals Inc. (AMEX: AEN)  

TooNiceStocks very popular Independent Research is being picked up by many news portals: 

TMCnet.com LINK HERE

Benzinga.com LINK HERE

Digitaljournal.com LINK HERE  


TooNiceStocks Initiates Coverage On YM BioSciences Inc. Digging Deeper Into The Bullish Sentiment And Upcoming Catalyst In Early June 2011

Wednesday, March 16th, 2011 - YM BioSciences Inc. (AMEX: YMI)

TooNiceStocks very popular Independent Researched reports are being picked up by many news portals: 

TheStreet.com LINK HERE

Benzinga.com LINK HERE

Prbusinessnews.com LINK HERE 


 TooNiceStocks Initiates Coverage on Fibrocell Science Inc. Pending June 22, 2011 FDA Decision with Elevated Interest

Monday, March 7, 2011 - Fibrocell Science Inc. (OTCBB: FCSC) 

TooNiceStocks very popular Independent Researched reports are being picked up by many news portals: 

Benzinga.com LINK HERE

PRBusinessnews.com LINK HERE

Digitaljournal.com LINK HERE


 

TooNiceStocks Initiates Coverage on Javelin Pharmaceuticals Inc. (AMEX: JAV) on Looming Hospira Inc. (NYSE: HSP) Buyout

Thursdayday, May 27, 2010 - Javelin Pharmaceuticals Inc. (AMEX: JAV) 

Results after research article release - JAV @ $1.11 High $1.65= 48.55% Multi-Day Runner  *UPDATE* ON JUNE 29th ON BUYOUT @ $2.20 or up to 98%!

It warms our hearts when we hear our PREMIER VIP MEMBERS and the rest of our TNS Investment Community making great gains from our top notch research and due diligence reports. In particular, on (AMEX: JAV). Today JAV soared up 58% and is currently still sitting there as Hospira Inc. (HSP) said it would complete its offer to buy out the drug developer at the end of the month after two delays, in a deal valuing the company at about $141 million.

Our PREMIER VIP MEMBER "Cullendroid" was the biggest winner booking $6,000 in profits. Followed by 'Trich78" and then "Blackemo". All held LONG and all banked big profits because they followed our top notch research that NO OTHER INVESTMENT NEWSLETTER provides out there, we are real traders who do real research. This is why we continue to grow rapidly and are about QUALITY and NOT QUANTITY. If you havent read our research article on JAV, please do so here, this article was featured on FOX Business News, again we are REAL TRADERS that do REAL RESEARCH. Please visit our research page here.

Again Congrats to all of the TooNiceStocks Investment Community! 

TooNiceStocks very popular Independent Researched reports are being picked up by many news portals: 

DailyFinance.com - LINK HERE

IBTIMES NEWS LINK HERE 

FoxBusiness News LINK HERE

Street Insider News LINK HERE

BENZINGA News LINK HERE 


TooNiceStocks Initiates Coverage on Upcoming Crucial FDA Clinical Trial Results for Guided Therapeutics Inc. (OTXQB: GTHP)

Thursday, March 18, 2010 - Guided Therapeutics Inc. (OTXQB: GTHP)

Results after research article release - GTHP @ $1.08 High $1.45 = 37% Multi-Day Runner  

TooNiceStocks very popular Independent Researched reports are being picked up by many creditable news portals: 

ClinicalPharmacovigilance.com - LINK HERE

PRweb.com - LINK HERE

FoxBusiness News - LINK HERE

Trading Markets - LINK HERE


*Please Note that TooNiceStocks.com in no way has not been compensated for commercial advertising, business marketing or profiling any of above mentioned companies , rather we have initiated our own independent research and coverage as you can tell from our indepth analysis from our very popular due diligence articles.



Join our Free Newsletter!